228 filings
Page 3 of 12
8-K
7m3c9h
12 Feb 21
Entry into a Material Definitive Agreement
8:00am
8-K
g75duk7swcy me
14 Jan 21
Other Events
8:13am
8-K
p1e0d6junaw5tspo 0x
18 Dec 20
Entry into a Material Definitive Agreement
4:23pm
8-K
8vhwzmqqm3 i5d5
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
8-K
o6y18xhl p5511
11 Dec 20
Lexicon Pharmaceuticals Receives Fast Track Designation from the Fda for LX9211 for Diabetic Peripheral Neuropathic Pain
7:43am
8-K
rkzbaw 99sjodm
17 Nov 20
Results from Soloist and Scored Outcomes Studies
7:22am
8-K
ycqhrp k2rjwz13evmnt
29 Oct 20
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
7:02am
8-K
muie24
22 Oct 20
Entry into a Material Definitive Agreement
7:12am
8-K
cnh4s2
29 Sep 20
Unregistered Sales of Equity Securities
7:14am
8-K
kajfofa7 ffhvfh
24 Sep 20
Unregistered Sales of Equity Securities
7:12am
8-K
9h6rh2jyl
11 Sep 20
Lexicon Pharmaceuticals Completes the Sale of Xermelo to
4:11pm
8-K
k8rb0eitn9 j73xk6
8 Sep 20
Termination of a Material Definitive Agreement
5:02pm
8-K
5jp5gphg6756wifo7
4 Aug 20
Cost Associated with Exit or Disposal Activities
12:00am
8-K
2joxnq
30 Jul 20
Lexicon Pharmaceuticals Enters into Agreement
7:18am
8-K
u5yg x5zla4lsk45
30 Jul 20
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
a3i6n5l
15 Jul 20
Entry into a Material Definitive Agreement
5:06pm
8-K
fbt7 k13a7dcnqn
29 May 20
Termination of a Material Definitive Agreement
4:33pm
8-K
m3qfb brd
27 Apr 20
Entry into a Material Definitive Agreement
4:03pm
8-K
1qb9qhufotlpg ywt
27 Apr 20
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
311e8r xwh
12 Mar 20
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2019 Financial Results and Provides a Business Update
7:04am